By Dr. Kanwal Awan
Abstract:
Introduction
As we are in the era of newer therapies, so my presentation will
focus on the latest targeted/immunotherapies in the Upper
Gastrointestinal Tumors
Content
I will briefly discuss regarding upcoming & new FDA
approved targeted agents & their Mechanism of actions.
I will discuss regarding Her2/neu target therapies, Anti VEGFR
antibodies, Anti PD1 antibodies, NTRK fusion proteins &
Claudin 18.2 target therapies.
I will discuss new clinical trials that lead to approval of these
drugs.
Trial results & drug activity.
Discussion & Conclusion
Now there’s an era of upcoming newer agents, target therapies
& immunotherapies, and these are new rays of hope for our
terminal cancer patients.